



Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States

Call Scheduled for Monday, August 3, 2009 at 8:30 a.m. ET

PT. RICHMOND, Calif., Aug 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) will host a conference call to discuss its exclusive license and collaboration agreement with Purdue Pharmaceutical Products L.P. to commercialize Intermezzo((R)) (zolpidem tartrate sublingual tablet) in the United States. The FDA has established October 30, 2009 as the Prescription Drug User Fee Act (PDUFA) action date for the Intermezzo((R)) New Drug Application (NDA).

Conference Call Information

Date: Monday, August 3, 2009
Time: 8:30 a.m. ET
Dial-in (U.S.): 877-545-1490
Dial-in (International): 719-325-4864

A simultaneous web cast of the conference call will be available on the Investor Relations section of the Transcept website at www.transcept.com. A replay of the call will be available on the website shortly after the conclusion of the call until Monday, September 7, 2009.

A telephone replay of the conference call will be available beginning August 3, 2009 at 11:30 a.m. ET and ending on August 17, 2009. The replay telephone number is 888-203-1112 (U.S.) or 719-457-0820 (International), Replay Passcode: 5541799.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. For further information, please visit the company's website at: www.transcept.com.

Contacts: Transcept Pharmaceuticals, Inc.
Greg Mann
Director of Corporate Communications
(510) 215-3567
gmann@transcept.com

The Ruth Group
Investors / Media
Sara Ephraim Pellegrino / Jason Rando
(646) 536-7017 / 7025
spellegrino@theruthgroup.com
jrando@theruthgroup.com

SOURCE Transcept Pharmaceuticals, Inc.

<http://www.transcept.com>

Copyright (C) 2009 PR Newswire. All rights reserved